Combioxin SA

8 articles about Combioxin SA

• 

  BioSpace Global Roundup, May 7

  5/7/2020

  Pharma and life sciences companies from across the globe provide updates on their business and pipelines.
• 

  Biopharma Update on the Novel Coronavirus: May 4

  5/4/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.

• Combioxin Highlights Results from Successful CAL02-001 First-in-Human Trial Evaluating CAL02 in Severe Pneumonia at ESICM 2018

  10/24/2018

  Combioxin SA announced an Oral Presentation highlighting successful first-in-human clinical results with CAL02 in severe pneumonia patients in ICU, at the ESICM’s annual congress, LIVES 2018, in Paris today.

• Combioxin Announces an Oral Presentation on CAL02 clinical results at ESICM 2018

  10/18/2018

  Combioxin SA announced today that first-in-human clinical results with CAL02 in severe pneumonia patients in ICU will be presented during the ESICM’s annual congress, LIVES 2018, taking place October 20-24, 2018 in Paris, France.

• Combioxin Release: Data Monitoring Committee Unanimously Recommends Continuation Of Combioxin First-In-Human Clinical Trial With CAL02 In Patients With Severe Pneumococcal Pneumonia

  10/10/2017

• Anti-Bacterial Infection Specialist Combioxin Appoints Industry Veteran Jeffrey Jump As Chairman

  7/20/2017

• Combioxin Announces Oral Presentation Of Results From The CAL02-001 Clinical Trial At ECCMID 2017

  3/15/2017

• Combioxin Escalates To High Dose In CAL02-001 Trial In Patients With Severe Pneumococcal Pneumonia Following IDMC's Positive Recommendation

  8/9/2016